These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 23785172)

  • 21. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
    Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
    Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma.
    Munck Af Rosenschold P; Costa J; Engelholm SA; Lundemann MJ; Law I; Ohlhues L; Engelholm S
    Neuro Oncol; 2015 May; 17(5):757-63. PubMed ID: 25537018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
    Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
    Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
    Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
    Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
    J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
    Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
    J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
    Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of
    Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
    O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flare Phenomenon in
    Filss CP; Schmitz AK; Stoffels G; Stegmayr C; Lohmann P; Werner JM; Sabel M; Rapp M; Goldbrunner R; Neumaier B; Mottaghy FM; Shah NJ; Fink GR; Galldiks N; Langen KJ
    J Nucl Med; 2020 Sep; 61(9):1294-1299. PubMed ID: 32005771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
    Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of O-(2-[
    Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C
    Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
    Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
    J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Accuracy of MR Spectroscopic Imaging and
    Mauler J; Lohmann P; Maudsley AA; Sheriff S; Hoevels M; Meissner AK; Hamisch C; Brunn A; Deckert M; Filss CP; Stoffels G; Dammers J; Ruge MI; Galldiks N; Mottaghy FM; Langen KJ; Shah NJ
    J Nucl Med; 2024 Jan; 65(1):16-21. PubMed ID: 37884332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
    Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
    J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.